Histone Deacetylases as Targets for Multiple Diseases

Author(s): Jaiprakash N Sangshetti, Nikhil S Sakle, M.H.G. Dehghan, Devanand B Shinde

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 13 , Issue 7 , 2013

Become EABM
Become Reviewer
Call for Editor


Inhibition of Histone deacetylases (HDACs) has been emerged as important approach to reverse aberrant epigenetic changes associated with various cancerous and non-cancerous diseases. The field of histone deacetylase inhibitors (HDIs) is moving into a new phase of development. The structure of histone deacetylases is well-established and the active sites have been well identified. Various drugs targeting this enzyme are in the pipeline for the treatment of different diseases. Since first-generation HDAC inhibitors proved their clinical fruitfulness and also second generation inhibitors are rationally designed with improved specificity, experts believe that this class will emerge in the treatment of various diseases. Considering these facts present review focuses on HDACs and developments of HDIs in the treatment of various diseases.

Keywords: Histone deacetylase, Cancer, Non-cancer disorders.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 March, 2013
Page: [1005 - 1026]
Pages: 22
DOI: 10.2174/1389557511313070006
Price: $65

Article Metrics

PDF: 16